Schwannomin-interacting protein 1 (SCHIP1)

Schwannomin-interacting protein 1 (SCHIP1) is a cytoskeleton-associated scaffold protein originally identified as a binding partner of schwannomin/merlin, a tumor suppressor[2][4]. It features a C-terminal coiled-coil domain and is involved in identical protein binding, cytoskeletal organization, and the assembly of protein complexes at the node of Ranvier and axon initial segment in myelinated neurons[2][4]. SCHIP1 participates in the regulation of Hippo signaling and processes such as face morphogenesis, fibroblast migration, neuronal development, and organization of membrane-associated proteins[1][3]. It plays a critical developmental role in craniofacial morphogenesis and has been implicated in inherited neurodevelopmental syndromes with global brain malformation, developmental delay, and facial dysmorphism[1][3]. Disease associations also include familial meningioma and celiac disease[3]. SCHIP1 is not currently considered a classic therapeutic target (such as receptor, enzyme, transporter, or ion channel) and there are no reported drugs or biomarkers directly related to SCHIP1[3].

Other names

SCHIP-1SCHI1Schwannomin interacting protein 1IQCJ-SCHIP1